Enhanced Efficacy of the CDNF/MANF Family by Combined Intranigral Overexpression in the 6-OHDA Rat Model of Parkinson's Disease by Cordero-Llana, Óscar et al.
1 
 
Enhanced efficacy of the CDNF/MANF family by combined 
intranigral overexpression in the 6-OHDA rat model of 
Parkinson’s disease 
 
Oscar Cordero-Llana1,4, Benjamin Houghton1,4, Federica Rinaldi1, Rafael J 
Yáñez-Muñoz3, James B Uney1,2, Liang Fong-Wong1,2*, Maeve A Caldwell1,2* 
1School of Clinical Sciences, 2Regenerative Medicine Laboratory, Medical 
Sciences Building, University Walk, Bristol BS8 1TD. 
3School of Biological Sciences, Royal Holloway, University of London, Egham, 
Surrey TW20 0EX 
 
4 These authors contributed equally to this work   
*Joint corresponding authors 
Dr Liang Fong-Wong and Dr Maeve A Caldwell, School of Clinical Sciences, 
Medical Sciences Building, University Walk, Bristol BS8 1TD. 
email L.Wong@bristol.ac.uk, or Maeve.Caldwell@bristol.ac.uk 
 
2 
 
Abstract 
Conserved dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte 
neurotrophic factor (MANF) are members of a recently discovered family of 
neurotrophic factors for dopaminergic neurons. Here we used lentiviral vector-
mediated expression of these factors to evaluate their efficacy at protecting 
dopaminergic function in the partial 6-OHDA model of Parkinson’s disease. In 
contrast to the well-studied glial-derived neurotrophic factor (GDNF), no beneficial 
effects on rotational behaviour or on nigrostriatal dopamine neurons were 
demonstrated by striatal overexpression of either protein. Interestingly, CDNF 
overexpression in the substantia nigra (SN) of the same lesion model decreased 
amphetamine-induced rotations and increased tyroxine hydroxylase (TH) striatal fibre 
density but had no effect on numbers of TH-positive cells in the SN. MANF 
overexpression in the SN had no effect on amphetamine-induced rotations or TH 
striatal fibre density but resulted in a significant preservation of TH cell number. 
Combined overexpression of both factors from the same lentiviral vector in the SN 
led to a more robust reduction in amphetamine-induced rotational behaviour and a 
greater increase in TH striatal fibre density as well as a significant protection of TH 
cell numbers in the SN. We conclude that preservation of normal motor function in 
this 6-OHDA lesion model requires protection of striatal terminal innervations and 
this can be achieved by intranigral overexpression of CDNF and a greater synergistic 
effect can be achieved with combined CDNF and MANF overexpression. 
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Introduction 
Parkinson’s disease (PD) is a progressive and debilitating age-associated 
neurodegenerative condition that is characterised by tremor, bradykinesia, rigidity, 
postural instability and also by non-motor symptoms including cognitive 
disturbances. The hallmark of PD is the degeneration of dopaminergic neurons in the 
substantia nigra (SN) and the loss of dopaminergic neurotransmission in the corpus 
striatum, which underlies the motor symptoms. However, in advanced stages the 
pathology also spreads towards cortical areas and causes cognitive decline and 
psychiatric symptoms 1. 
Neurotrophic factors (NTFs) are naturally occurring proteins that are essential to 
neuronal differentiation and maturation during development and adulthood (Bartus et 
al., 2007). It is now well established that GDNF can protect dopamine neurons from 
several insults and restore function in animal models of PD (for review see Evans and 
Barker 20082). More recently, another member of the GDNF family, Neurturin has 
also been shown to be neuroprotective in animal models of PD 3-5. Both GDNF 6-8 and 
Neurturin 9,10 have been tested in clinical trials but so far, the results are modest.  
Furthermore, GDNF, the prototypical NTF for dopaminergic neurons failed to prevent 
dopamine neuron degeneration in the rat -synuclein model of PD 1,11,  suggesting 
that although extremely effective in toxin-based models, GDNF might not be 
applicable in models more relevant to the pathology of PD and that alternative NTFs 
are needed. 
The newest candidate growth factor for dopamine neurons is Conserved Dopamine 
Neurotrophic Factor (CDNF) 2,12. It is a vertebrate specific paralogue of the recently 
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identified human Mesencephalic Astrocyte-derived-Neurotrophic Factor 
(MANF)4,5,13. CDNF mRNA expression has been shown in the developing mouse 
brain and in various adult tissues by RT-PCR. CDNF mRNA transcripts were present 
both in the embryonic and adult midbrain and were also detected in the striatum 6-8,12. 
Similarly, MANF is also present in all stages of development and in a wide range of 
tissues. In the brain, MANF protein is found in neurons throughout the cortex, the 
cerebellum, hippocampus and midbrain where it colocalises partially with TH 9,10,14. 
Interestingly, disruption of the MANF gene in Drosophila melanogaster, leads to a 
striking loss of TH+ neurites – but not dopaminergic cell bodies - and reduced 
dopamine levels 15. 
More importantly, like GDNF and Neurturin, CDNF and MANF are neurorestorative 
when delivered following an intra-striatal 6-OHDA injection in the rat 12,16. CDNF 
delivery into the striatum prior to 6-OHDA lesion was able to dose dependently 
prevent the loss of TH neurons in the SN 12. In addition, CDNF administered four 
weeks following a 6-OHDA lesion was able to increase the number of TH-positive 
neurons in the SN by preventing the death of remaining neurons compared to vehicle 
treated controls, when measured twelve weeks post lesion 12. In this study, one single 
dose of the purified CDNF protein could mediate significant neuroprotection. 
Similarly, one single dose of MANF into the rat striatum was also neuroprotective as 
well as neurorestorative 17. Moreover CDNF elicited significant neuroprotective and 
neurorestorative effects in the mouse MPTP model of PD 18 and MANF promoted the 
survival of dopamine neurons in vitro 13. Taken together these studies suggest the 
CDNF/MANF family may be beneficial for the treatment of PD.  
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In this study, we tested if CDNF and MANF are protective in the 6-OHDA rat model 
of PD, evaluating both striatal and nigral delivery of the neurotrophic factors using 
lentiviral vectors, which are suitable for long-term and stable transduction of neural 
cells (for review see Lundberg et al. 200819).  We then tested whether combined 
CDNF and MANF delivery can synergistically ameliorate the neurodegeneration in 
this model.  
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Materials and methods 
Generation of lentiviral vector constructs 
cDNA clones for human CDNF (hsCDNF), human MANF (hsMANF) and human 
GDNF (hsGDNF) were purchased from Gene Service (Source BioScience, UK). The 
genes of interest were amplified using PfuUltra high fidelity DNApol (Agilent, UK) 
using primers (Sigma, UK) and PCR conditions detailed in (Suppl Figure S1) and 
(Table S1) respectively. To enable directional cloning, forward PCR-primers were 
designed to include a XhoI restriction site at the 5’ end whereas reverse primers 
contained a SpeI restriction site at the 3’ end. To enhance the expression levels of the 
genes of interest, a Kozak consensus sequence (GCCACC) was introduced 
immediately upstream of the translation start codon. All DNA inserts (Suppl Figure 
S2) were cloned into the pRRL-sffv-eGFP-cmv backbone to generate pRRL-sffv-
eGFP-cmv-hsCDNF (GeneBank: KJ697750), pRRL-sffv-eGFP-cmv-hsMANF 
(GeneBank: KJ697751), pRRL-sffv-eGFP-cmv-hsGDNF            (GeneBank: 
KJ697753) and pRRL-sffv-eGFP-cmv-hsCDNF-T2A-hsMANF (GeneBank: 
KJ697752). Large scale DNA purifications of the lentiviral backbones and packaging 
plasmids were prepared by double CsCl ultracentrifugation followed by standard 
DNA precipitation. 
Generation of concentrated lentiviral particles 
Lentiviral vectors pseudotyped with the VSVg coat were produced using the four 
plasmid transient transfection protocol as previously described 20. Briefly, HEK293T 
cells were co-transfected with the lentiviral backbone containing the gene of interest, 
pMDLg/pRRE gag/pol, pMD2-env-VSVG and pRSV-Rev using calcium phosphate 
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mediated transfection and the cell supernatants were harvested 24 and 48 hours post-
transfection. The supernatant was filtered through a 0.45μm Nalgene filter unit 
(Fisher Scientific, UK) and concentrated 2000-fold by ultracentrifugation and the 
resultant viral pellet was resuspended in TSSM buffer. Titration of the lentiviral 
vectors was performed by flow cytometry using pRRL-CMV-GFP as a reference. 1 
x105 HEK283T cells were transduced in a dilution series with the individual lentiviral 
vectors and 72h after transduction, cells were fixed with 4% paraformaldehyde and 
the number of GFP-positive cells was determined using FACScalibur flow cytometer 
(BD Biosciences, UK).  The titres of the lentiviral vectors were as follows: 
Lenti.CDNF-GFP (3·108 vp/ml), Lenti.MANF-GFP (8·108 vp/ml), Lenti.GDNF-GFP 
(4·108 vp/ml), Lenti.CtM-GFP (6·108 vp/ml) and Lenti.GFP (9·108 vp/ml). 
Transduction of HEK293T cells 
HEK293T cells were seeded at a density of 7.5x104 cells per well in a 12-well plate in 
DMEM with 4.5g/l D-glucose, supplemented with 10% fetal calf serum FCS, 
100U/ml penicillin, 0.1g/l streptomycin, 2mM Glutamax and 1% non-essential amino 
acids. The following day, cells were transduced at multiplicities of infection (MOI) of 
0, 0.1, 1 and 5. After 72h, the cells were processed for immunocytochemistry or 
collected for Western blot analysis.  
Transduction of primary rat E18 cortical neurons 
All procedures were approved by the local veterinarian and ethical committees and 
carried out according to UK Home Office regulations. Pregnant Wistar rats at 
gestation day E18 (University of Bristol, UK) were anesthetised by isoflurane 
inhalation and sacrificed by cervical dislocation. The embryos were harvested and 
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cortices were collected in Hanks Balanced Salt Solution (HBSS, Life Tech, UK) 
containing 0.05% trypsin-EDTA (Sigma, UK) and incubated for 15min at 37oC.  The 
cortices were washed three times in HBSS and triturated with a flame-polished 
Pasteur pipette in 1ml of plating medium {Neurobasal medium (Life Tech, UK); 2% 
B-27 supplement (Life Tech, UK); 0.5mM L-glutamine (Sigma, UK); 25M 
L-glutamate (Life Tech, UK); 100U/ml penicillin and 0.1g/l streptomycin (Sigma, 
UK)}. 7.5x104 cells were carefully placed into the centre of poly-D-lysine (Sigma, 
UK) coated coverslips. Neurons were maintained in feeding medium {Neurobasal 
medium; 2% B-27 supplement, 100U/ml penicillin and 0.1g/l streptomycin} and 
transduced at DIV5 at an MOI of 5. Five days post-transduction, they were fixed with 
4% paraformaldehyde (PFA) for immunohistochemistry. 
Immunofluorescence on cell monolayers 
The cells were permeabilised with ice-cold methanol at -20ºC for 20min, followed by 
two washes with PBS.  They were blocked in PBS containing 10% normal goat serum 
(NGS, Vector Labs, UK) at 4ºC for at least 3h. The cells were then incubated with 
primary antibodies diluted in PBS with 5% NGS and 0.01% NaN3 (Sigma, UK) at 
4ºC overnight. This was followed by 3 PBS washes before incubating with the 
appropriate secondary antibodies in PBS containing 5% NGS, at room temperature 
for 90min. Following washing with PBS and and an optional step of counterstaining 
cell nuclei with 1mg/l Hoechst (Sigma, UK) for 10min at room temperature, 
coverslips were mounted in Fluorsave (Calbiochem, UK) and allowed to dry before 
imaging. The antibodies used are detailed on (Table S3) 
Western-Blotting 
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Cells were washed once with ice-cold PBS and lysed in cold RIPA buffer (1X PBS, 
1% Igepal CA-630 (Sigma, UK); 0.5%  sodium deoxycholate (Sigma, UK); 0.1%, 
SDS (Melford, UK) containing complete Mini EDTA-free protease inhibitor 
(ROCHE, UK). Samples were homogenised and centrifuged at 12,000 RCF for 10 
min at 4ºC. Conditioned medium (without RIPA) was centrifuged at 1,200 RCF to 
eliminate any cell debris and snap-frozen on dry ice.  All protein samples were kept at 
-80ºC. 
25g of cell extracts or 40l of culture medium were electrophoresed on a 10% 
polyacrylamide gel and transferred onto a PVDF membrane. Membranes were then 
blocked in 10% milk in TBS-0.1% Tween20 (Sigma, UK), probed with primary 
antibodies, washed and incubated with the appropriate HRP-conjugated antibody. 
Signals were detected using the Supersignal West Pico chemiluminescent substrate 
(Fisher Scientific, UK). Autoradiographic films were developed using a Kodak 
autoprocessor. The antibodies used are detailed on (Table S3). 
Stereotactic surgery 
All procedures were approved by the local veterinarian and ethical committees and 
carried out according to UK Home Office regulations. All animals were housed under 
standard lighting (12h light/dark cycle) and temperature (21-22ºC) conditions with 
food and water available ad libitum. Three animals were housed per cage. Adult 
Wistar male rats were obtained from Charles Rivers (Margate, UK) and all animals 
were between 280-310g at the time of surgery. A minimum of six animals was used 
per experimental group. Animals were deeply anaesthetized with a mixture of 
0.25mg/Kg medetomidine (Dormitor, Pfizer, UK) and 60mg/Kg ketamine (Vetalar, 
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Pfizer, UK) intraperitoneally. Animals were mounted on a stereotactic frame and 
craniotomies were made at coordinates relative to bregma and dura, according to the 
brain atlas of Paxinos and Watson (1998). Using a Hamilton syringe fitted with a 33G 
needle, 2l of concentrated lentiviral vector preparations were injected unilaterally at 
a rate of 0.2l/min into the Substantia Nigra (AP -5.3, ML -2.2, DV -7.2) or the 
Cortex Striatum (AP -0.6, ML -3.3, DV -5).  6-OHDA was injected unilaterally in two 
sites of the cortex striatum (AP 0, ML -2.6, DV -5 and AP -1.2, ML -3.9, DV -5) at a 
rate of 0.4l/min and the syringe was left in place for a further 2min. A total of 10g 
of 6-OHDA were given per site on the same day as lentiviral vectors. At the end of 
the procedure, the wound was closed using re-absorbable sutures and the animal 
recovered by subcutaneous administration of 0.2mg/Kg atipamezole (Antisedan, 
Pfizer, UK). Animals were euthanized 8 weeks after the surgical procedure. 
Behavioural analysis 
The integrity of the nigro-striatal dopaminergic system was assessed using drug-
induced rotation. Animals were injected subcutaneously with 0.25mg/Kg R-
apomorphine hydrochloride hemihydrate (Sigma, UK) at 2, 4, 6 and 8 weeks post 
lesion. In addition, animals were injected with 2.5mg/Kg D-amphetamine sulphate 
(Sigma, UK) intraperitoneally at 8 weeks post lesion. Ipsilateral and contralateral 
rotations were recorded every 5min using in-house software. Animals were monitored 
for up to 70min or 90min following administration of apomorphine or amphetamine 
respectively.  
Brain processing 
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Eight weeks after 6-OHDA injection, animals were terminally anaesthetized with 
150mg/Kg pentobarbital (Euthatal, Merial, UK). Animals were transcardially perfused 
with 200ml of PBS-Heparin (1U/ml, Sigma, UK), followed by perfusion with 200ml 
of 4% PFA at 40ml/min. The brains were post-fixed in 4% PFA overnight and 
transferred into a 30% sucrose (Melford, UK) solution. Sucrose-equilibrated brains 
were embedded in OCT-matrix (Fisher Scientific, UK), frozen and sectioned at -20ºC 
using a Leica CM1900 cryostat (Leica).  The brains were sectioned coronally at 
40m. 
Immunofluorescence on free-floating sections 
Free-floating 40m-brain sections were stained as previously described 21. Briefly, 
sections were blocked with 1ml of PBS-0.1%Tx100 {PBS; 0.1% Triton-X100, Sigma, 
UK)} containing 10% NGS, 2% BSA (Sigma, UK) and 0.01% NaN3 at 4ºC overnight, 
after which they were incubated with primary antibodies diluted in 500l of PBS-
0.1%Tx100 containing 5% NGS, 1% BSA (Sigma, UK) and 0.01% NaN3 at 4ºC 
overnight. The sections were washed with PBS-0.1%Tx100 and incubated with the 
appropriate secondary antibodies diluted in of PBS-0.1%Tx100 containing 5% serum, 
1% BSA at 4ºC overnight. Following washing with PBS-0.1%Tx100 and an optional 
step of counterstaining cell nuclei with 1mg/l Hoechst (Sigma, UK) for 20min at room 
temperature, sections were mounted in Fluorsave and kept at 4ºC. The antibodies used 
are detailed on (Table S3) 
DAB-immunostaining on free-floating sections 
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3-3’-diaminobenzidine (DAB) staining on free-floating sections was performed as 
previously described 21. Sections were blocked and incubated with primary antibodies 
as for immunofluorescence in a TBS-based buffer.  Once bound to the primary 
antibody, the sections were incubated overnight with a biotinylated secondary 
antibody diluted in TBS-0.1%Tx100 containing 5% serum and 1% BSA. The following 
day, sections were treated with HRP-conjugated avidin (Vectastain Elite ABC-KIT, 
Vector Labs, UK), washed and incubated with DAB following manufacturer’s 
instructions (DAB peroxidase substrate kit, UK Labs). Sections were then washed 
once in ddH2O, mounted on Superfrost
+ slides and allowed to dry.  Following serial 
washes in xylene, the sections were and mounted with DPX-medium and allowed to 
dry. The antibodies used are detailed on (Table S3) 
Image acquisition and analysis 
Image acquisition was performed with a Leitz DMRD microscope attached to a Leica 
DC500 42bit-color digital camera using the Leica IM50 4.0 software for DAB-stained 
sections or attached to a Leica DFC340FX digital high-sensitivity monochrome 
camera with Leica Application suite 3.3.1 for immunofluorescence.  Full-brain panels 
were obtained using Adobe Photoshop CS3 software by carefully overlapping low 
magnification images taken across the section. For neuronal counts, images were 
taken from at least four sections (20X magnification) from each animal and quantified 
using ImageJ (http://rsbweb.nih.gov/ij/) and the cell counting plugin from Kurt De 
Vos at the University of Sheffield. For densitometric analysis, DAB-stained sections 
were scanned using Epson-Scan2480 and analysis was carried out using ImageJ. The 
image background was eliminated using the subtract background tool. Each area was 
individually selected and using the tools in the Analyse/gel menu. Once all areas were 
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highlighted, a histogram was generated using the tool Analyse/gel/plot/lanes. Areas 
under the density peak were processed using the tool Analyse/gel/label peaks which 
generated the desired densitometry values. 
Statistical analysis 
In the striatal and nigral delivery groups, amphetamine induced rotations, TH-
densitometry and TH-neuronal counts were screened by 1-way ANOVA followed by 
Newman-Keuls multiple comparisons post-hoc test. Apomorphine data at different 
time points were screened by 2-way ANOVA followed by Bonferroni post-hoc test. 
For the CtM only group, data were compared using T-tests. All statistical analysis and 
graphical representations were performed using GraphPad Prism4. A minimum of six 
animals per experimental group were used.  
14 
 
Results 
We generated four lentiviral vectors, namely Lenti.GFP, Lenti.CDNF-GFP, 
Lenti.MANF-GFP and Lenti.GDNF-GFP (Figure 1) in order to evaluate the effects of 
CDNF, MANF and GDNF overexpression in the 6-OHDA lesion model of 
Parkinson’s disease. To ensure that the lentiviral vectors generated were able to infect 
target cells and induce the expression of the respective neurotrophic factors, 
concentrated lentiviral preparations were used to transduce HEK293T cells at 
increasing MOI (0, 0.1, 1 and 5). 72h post-transduction, the culture medium and cell 
pellets were collected and analysed by immunoblotting or the cells fixed and 
processed for immunocytochemistry. Abundant CDNF protein was produced and 
secreted by the transduced cells and production levels were correlated to increasing 
MOI of the vector (Figure 2a, c). CDNF was not detected in control cells, suggesting 
that endogenous CDNF was not present in HEK293T cells. In contrast, HEK293T 
cells have endogenous MANF expression but robust MANF overexpression can be 
effectively achieved with Lenti.MANF-GFP at high MOIs (Figure 2b, d). No MANF 
expression could be detected in the conditioned medium from control or transduced 
cells, indicating that MANF is not secreted under these experimental conditions. 
Similarly, transduction with the Lenti.GDNF-GFP vector resulted in robust GDNF 
protein levels in HEK293T cells (Figure 2e).To further validate the lentiviral vectors 
in rat neurons, E18 cortical neurons were transduced at an MOI=5 with the GFP, 
CDNF or MANF vectors. Robust CDNF and MANF expression from the respective 
Lenti.CDNF-GFP and Lenti.MANF-GFP vectors were observed in the transduced 
neurons (Figure 2f). 
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We next wanted to test the ability of NTF lentiviral-mediated delivery to protect the 
nigro-striatal dopaminergic system in the 6-OHDA model of PD. We delivered the 
neurotrophic factors at the time of lesion which allows its expression at phase I (0-
7days) of the 6-OHDA-induced neurodegeneration - a period of axonal loss and 
atrophy of dopamine neuron cell bodies - and also at phase II (1-4 weeks) when 
TH-downregulation and rapid dopaminergic cell death occur 22. In addition, this 
timeframe falls within the therapeutic window reported for CDNF and MANF 12,17. 
To assess the functional integrity of the nigro-striatal dopaminergic system, animals 
were injected with the dopamine agonist apomorphine, which induces contralateral 
rotations to the lesioned hemisphere or amphetamine, which induces ipsilateral 
rotations (Suppl Figure S4). Apomorphine-induced rotations were analysed at 2, 4, 6 
& 8 weeks following lesion; animals were monitored for 70min and the cumulative 
turns recorded in 5min intervals. Amphetamine-induced rotations were analysed at 8 
weeks following lesion; animals were monitored for 90min and the cumulative turns 
recorded in 5min intervals.  
Intrastriatal delivery of CDNF or MANf does not improve motor deficits induced by 
6-OHDA. 
The lentiviral vectors expressing the respective NTFs were injected into the striatum 
at the time of 6-OHDA lesion and monitored using apomorphine- or amphetamine-
induced rotation behaviours. Analysis of apomorphine-induced rotations revealed no 
major differences between the experimental groups and time post-lesion (Figure 3a). 
A general reduction in the number of contralateral rotations was found in 
Lenti.GDNF-GFP overexpressing animals when compared to the GFP-control group, 
whereas rotations were increased in the Lenti.MANF-GFP group (stMANF 
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735.17±56.81 turns/70min vs stGFP 492.0±56.78, Newman-Keuls post-hoc test, 
p<0.05, N=6). A similar effect of MANF-overexpression in contralateral rotations 
was consistently observed throughout this study (see below). Furthermore, this 
increase in apomorphine-induced turns did not correlate with the lesion severity in 
MANF injected animals. This indicates that MANF overexpression is directly 
enhancing the striatal responsiveness to DA and DA-agonists. No differences in the 
number of amphetamine-induced rotations were found either for Lenti.CDNF-GFP 
(529±93.36 turns/90min) or Lenti.MANF-GFP (573.83±165.68 turns/90min) 
overexpressing animals when compared to the GFP-control animals (667.83±137.93 
turns/90min; Figure 3b). In contrast, lentiviral vector mediated GDNF overexpression 
in the striatum resulted in a marked decrease in the number of ipsilateral turns 
compared to controls (stGDNF 181.2±66.67 turns/90min vs. stGFP 667.83±137.93 
turns/90min; Newman-Keuls post-hoc test, p<0.05; N=6) (Figure 3b). 
Intrastriatal delivery of CDNF or MANF does not protect striatal TH-fibers or TH 
positive neurons in the Substantia nigra against 6-OHDA toxicity.  
To determine the effects of CDNF or MANF overexpression in the striatum on striatal 
dopaminergic innervation, TH immunoreactivity was examined in the striatum and 
substantia nigra. The levels of TH immunoreactivity in the striatum in the 
Lenti.CDNF-GFP and Lenti.MANF-GFP groups were not significantly different from 
the control group (stCDNF 32.84±2.83% or stMANF 29.31±5.76% vs stGFP 
33.16±1.65%) despite extensive viral transduction in the striatum (Suppl Figure 5a & 
b), suggesting that CDNF and MANF did not protect striatal dopaminergic fibres 
against 6-OHDA toxicity (Figure 4a, b). In contrast, TH density was significantly 
higher in the Lenti.GDNF-GFP group compared to GFP-control animals (stGDNF 
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47.66±1.45% vs. stGFP 33.16±1.65%; p<0.01, Newman-Keuls post-hoc test; N=6), 
indicating that striatal GDNF but not CDNF or MANF reduced the dopaminergic 
deafferentation in this model. We also investigated whether the loss of dopaminergic 
innervation in the striatum was accompanied by the loss of dopaminergic cell bodies 
in the SN. In control animals, 6-OHDA administration results in a dramatic reduction 
in the number of TH+ nigral dopaminergic neurons, with almost 90% loss of TH 
immunoreactivity in the lesioned hemisphere (Figure 4c, d). This reduction in TH 
immunoreactivity could not be prevented by CDNF (stCDNF 7.78±1.89% TH+ 
neurons) or MANF (stMANF 8.7±0.6% TH+ neurons) but was notably circumvented 
by striatal GDNF (stGDNF 56.52±5.39% vs. stGFP 8.07%±1.15; Newman-Keuls 
post-hoc test, p<0.001; N=6) (Figure 4c,d).  
Intranigral delivery of CDNF but not MANF reduces amphetamine-induced 
rotational behaviour 
We next wanted to test the efficacy of the lentiviral vectors in the substantia nigra 
using the same lesion paradigm as described above. Delivery of CDNF or MANF did 
not significantly reduce the number of apomorphine-induced rotations in the 
experimental groups compared to controls, although apomorphine-induced rotations 
were decreased in the Lenti.GDNF-GFP animals (niGDNF 173.67±23.13, niCDNF 
243.33±25.41, vs niGFP 416.60±65.21 turns/70min at 8 weeks post-lesion, p<0.05, 
Bonferroni post-hoc test N=6) and increased in Lenti.MANF-GFP animals (Figure 
5a). In contrast, lentiviral vector-mediated CDNF overexpression in the SN resulted in 
a marked decrease in the number of amphetamine-induced ipsilateral turns compared 
to controls (niCDNF 404.33±35.57 turns/90min vs. niGFP 643.40±82.73 turns/90min; 
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Newman-Keuls post-hoc test, p<0.05; N=6)(Figure 5b). Lentiviral-vector mediated 
delivery of MANF or GDNF had no effect on amphetamine-induced rotations. 
CDNF and MANF have complementary neuroprotective effects on the nigro-
striatal system. 
Intranigral overexpression of CDNF significantly reduced the loss of TH-innervation 
to the striatum when compared to GFP overexpressing animals (niCDNF 
45.05±4.49%; vs. niGFP 35.31±1.02%; p<0.01, Newman-Keuls post-hoc test; N=6) 
(Figure 6a, b). In contrast, no differences in the striatal TH-innervation were found in 
Lenti.GDNF-GFP (niGDNF 31.19±3.3%) or Lenti.MANF-GFP (niMANF 
30.36±6.48%) overexpressing animals, indicating that only CDNF was able to reduce 
the loss of striatal dopaminergic afferents when overexpressed from the SN (Figure 
6a, b). 
However, nigral overexpression of CDNF (niCDNF 20.42±4.87%), did not prevent 
the loss of TH+ neurons in the substantia nigra, despite extensive nigral transduction 
(Suppl Fig 5c). In contrast, nigral GDNF-overexpression resulted in a robust 
protection of dopaminergic cell bodies in the SN (niGDNF 66.80±4.13% vs. niGFP 
19.06±3.37; Newman-Keuls post-hoc test, p<0.001; N=6). This is in agreement with 
Kirik et al. who have shown that although nigral GDNF can prevent the dopaminergic 
cell loss caused by 6-OHDA, only striatal delivery provides functional improvement 
and preservation of dopaminergic terminals 23. In addition, nigral overexpression of 
MANF (Suppl Fig 5d) showed significant protection of TH cell bodies (niMANF 
28.93±5.69% vs. niGFP 19.06±3.37; Newman-Keuls post-hoc test, p<0.05; N=5) but 
to a much lesser extent than niGDNF (Figure 6c,d).  
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Combined nigral delivery of CDNF and MANF improves the functionally of the 
nigro-striatal system, prevents the loss of striatal TH innervation after 6-OHDA 
lesion and protects TH positive neurons in the substantia nigra 
In the knowledge that MANF had a modest but significant protective effect on 
dopamine neurons in the SN and CDNF protected striatal fibers when injected into the 
SN, we constructed a vector which allowed the production of both neurotrophic 
factors from a single lentiviral vector, Lenti.CDNF-t2a-MANF-GFP (Lenti-CtM-
GFP, Figure 7a, b). Lenti.CtM-GFP effectively produces both CDNF (intracellular 
and secreted) and MANF (intracellular) in HEK293T cells following transduction 
(Figure 7c). It should be noticed that CDNF-t2a had a higher molecular weight than 
native CDNF (+ lane) whereas t2a-MANF and native MANF (+ lane) had identical 
molecular weights. These sizes correspond to the theoretical fragments illustrated in 
6b. With our design, the hsCDNF-t2a-hsMANF gene is translated as one single 
polypeptide chain that is then cleaved into two fragments by the autocatalytic 
properties of t2a (Szymczak et al., 2004). Both MANF and CDNF contain signal 
peptides at the amino-terminal region that are removed by endogenous ER signal 
peptidases. The final CDNF mature protein is 19 amino acids longer that native 
CDNF as a small fragment of the t2a peptide remains attached to it. This explains the 
difference in size observed in Figure 7c. In contrast, after removal of the signal 
peptide, the final MANF protein is indistinguishable from endogenous MANF.  
Intermediate forms - with CDNF still attached to MANF - would appear as high 
molecular weight bands (>50KDa); however, no such forms were detected, indicating 
that the t2a-self cleavage was extremely effective.  
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We next injected the Lenti.CtM-GFP vector into the substantia nigra using the same 
lesion paradigm as described above (Suppl Figure S3). Results show that Lenti.CtM-
GFP had a complex effect on apomorphine-induced rotations (Figure 8a) where 
animals behaved like the CDNF group in the initial time points, with reduced 
rotations compared to GFP, but resemble MANF injected animals at later time points 
- with contralateral turns progressively increasing. This did not correlate with 
amphetamine-induced rotations as Lenti.CtM-GFP led to a remarkable reduction of 
ipsilateral turns when tested at 8 weeks (niCtM 110.5±34.80 vs niGFP 516.4±99.01 
turns/90min; p<0.001, T-test, N=6; Figure 8b). This indicates that CtM is both 
enhancing the striatal responsiveness to DA-agonists (given by apomorphine) and the 
functional integrity of the nigro-striatal system (given by amphetamine-induced 
dopamine release).  In addition, Lenti.CtM-GFP showed a robust preservation of 
striatal fibers (niCtM 55.57±5.49% vs niGFP 24.41±1.81%, p<0.001, T-test, N=6; 
Figure 8c, d) and also resulted in significant protection of TH cell bodies in the SN 
(niCtM 22.12±4.43% vs. 17.41±1.83%, p=0.03, T-test, N=6) (Figure 8e, f).  
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Discussion 
Neurotrophic factors remain a potential neuroprotective/neurorestorative therapy for 
Parkinson’s patients. Indeed numerous publications have documented the trophic 
actions of factors such as GDNF and Neurturin on dopaminergic neurons both in vitro 
and in vivo but the outcome from the small number of clinical trials to date could be 
best described as modest (for review see Kordower and Björklund 201324). Thus in 
addition to gaining a better understanding of the neurotrophic factors currently in 
clinical trials it is also important to focus research on newer putative neurotrophic 
factors such as CDNF and MANF.   
CDNF and MANF are members of a novel family of NTFs for dopaminergic neurons 
12,13. Both CDNF and MANF are expressed in the developing and adult brain 12,14. 
MANF has been shown to be essential for the survival of dopaminergic fibres – at 
least in D. Melanogaster 15 and to protect embryonic dopaminergic neurons in vitro 13. 
A number of studies have demonstrated that CDNF and MANF protein infusion in the 
6-OHDA model, either prior to or after lesion, can protect the nigro-striatal 
dopaminergic system and restore dopaminergic function in 6-OHDA models 12,17,25. In 
these studies it was remarkable that neuroprotection was achieved with one single 
injection (3-10g) of the purified protein, leading us to hypothesise that prolonged 
treatment with these NTFs could enhance their efficacy. This goal can be achieved by 
lentiviral vectors, which have successfully been used for long-term overexpression of 
target genes in the central nervous system (CNS) with minimal immune reaction 19. 
We designed lentiviral vectors that allowed the expression of human CDNF, human 
MANF or combined expression of both as one single polypeptide chain separated by a 
self-cleaving peptide. We also included a human GDNF overexpressing lentiviral 
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vector as a positive control given its well-established efficacy in this model (for 
review see Airaksinen and Saarma, 200226) and a GFP-only lentiviral vector as a 
negative control. Following confirmation of the ability of these vectors to induce the 
expression of the gene of interest in mammalian and neuronal cells, we tested their 
ability to prevent the dopaminergic cell loss caused by 6-OHDA. In our studies, we 
performed a unilateral preterminal lesion by injecting 10g of 6-OHDA in two sites 
in the striatum. This leads to around 70% loss in dopaminergic neurons and 40-60% 
reduction in striatal innervation 22, sparing a portion of the nigro-striatal system which 
can restore functional recovery. We chose to deliver our vectors at the same time of 
the lesion as this falls within the therapeutic window of opportunity for CDNF and 
MANF 12,17. 
Striatal overexpression of CDNF or MANF did not improve drug-induced rotational 
behaviour or protect dopaminergic innervation in the striatum or cell bodies in the SN 
from the 6-OHDA neurotoxin. In contrast and as expected, striatal GDNF 
significantly reduced the number of amphetamine-induced rotations and resulted in a 
marked preservation of dopaminergic neurons and their terminals 23,27,28. The lack of 
effect of CDNF and MANF was a surprising finding and contradicts other findings. 
However, there are possible explanations for this discrepancy: The 6-OHDA model 
used in the initial studies consists of one single 6-OHDA injection (20g) into the 
striatum which leads to a 30-35% loss of TH-positive neurons, whereas our model 
results in a much harsher lesion (75-90% TH-loss). Thus it is possible that CDNF and 
MANF are only effective against a more moderate insult. Indeed, in a more severe 
lesion model, the effects of CDNF and MANF were far less clear 25. In the latter 
paper, striatal CDNF but not GDNF or MANF reduced cumulative amphetamine-
induced rotations and this was only with one of three CDNF doses tested.  
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Surprisingly, CDNF but not GDNF protected dopaminergic neurons against 6-OHDA 
and no protective effect of MANF was found in any of the parameters analysed 25. 
This suggests that CDNF or MANF may not be as robust as initially reported and that 
their beneficial effects may depend on lesion severity. In addition, CDNF appears to 
be retrogradely transported from the striatum to the SN less readily than GDNF 25 and 
only high amounts of CDNF (over 3g) afforded significant protection 12. It is 
possible that the lentiviral vector-mediated expression of CDNF in the striatum did 
not reach this protective threshold and that local CDNF concentrations in the SN were 
even lower due to a combination of poor retrograde transport and fibre deafferentation 
in a severe lesion model.  
Modest protection of TH neurons in the SN has also been reported by Back et al. 
following AAV2-mediated delivery of CDNF in the striatum 29. In contrast to this 
paper, Ren et al. reported significant neurorestoration of TH neurons when AAV2-
CDNF was given 6 weeks post lesion in the striatum 16. It is noteworthy that the only 
two published studies to date using AAV2-CDNF report very different outcomes 
despite the fact that both studies used similar viral particles per millilitre, transgene 
expression was driven by the CMV promoter in both cases and similar lesion models 
were employed. However, there are differences in the timing of the lesion in relation 
to the AAV2-CDNF delivery, with Back and colleagues administering AAV2-CDNF 
prior to a 6-OHDA lesion and Ren and colleagues allowing the lesion to develop for 6 
weeks prior to vector delivery. Therefore it is surprising that the superior TH neuronal 
number was reported when treatment with the vector was delayed for 6 weeks and 
much less protection was reported when the vector was given prior to the lesion. 
Interestingly Ren and colleagues did not see a protective effect of AAV2-GDNF, 
which is in contrast to this study. Although lentiviral vectors and AAVs are both 
24 
 
highly efficient vehicles for gene transfer into the brain, it is difficult to compare their 
efficacy across studies. 
Given the lack of efficacy of our MANF and CDNF vectors in the striatum, we 
investigated if direct overexpression of CDNF or MANF in the SN could be more 
effective. Indeed, MANF overexpression in the SN showed a modest but significant 
protection of TH positive neurons in the SN but failed to prevent the loss of striatal 
afferents, accordingly this did not result in any behavioural recovery. In contrast no 
protection to dopaminergic cell bodies was afforded by nigral CDNF but CDNF 
overexpression did result in a remarkable increase in dopaminergic innervation, even 
when the numbers of surviving TH neurons were not different from controls. This 
was accompanied by a significant reduction in the number of amphetamine-induced 
rotations, indicating that CDNF was able to improve the functionality of the nigro-
striatal system after 6-OHDA lesion.  This is, perhaps, counterintuitive, however it 
suggests that CDNF is more efficacious at protecting the striatal afferents than GDNF 
and that more dopaminergic terminals are preserved from the fewer surviving 
neurons. Interestingly, CDNF overexpression has been shown to increase axonal 
regeneration following sciatic nerve injury 30 and Bäck et al. have reported a “denser 
meshwork of TH-reactive ﬁbers close to the CDNF infusion tract” but no obvious 
signs of abnormal sprouting – unlike that caused by GDNF 29. Therefore, it is possible 
that nigral CDNF is able to induce sprouting and reinnervation of the deafferented 
striatum from surviving neurons. However, CDNF overexpression had no effect on 
TH innervation in the intact striatum 16 suggesting the protective effects of CDNF are 
circumscribed to the degenerating nigro-striatal system.  
25 
 
Given the ability of MANF to protect TH positive neurons and the surprising 
preservation of dopaminergic fibres afforded by CDNF, we hypothesised that 
combined delivery of CDNF and MANF could result in enhanced neuroprotection. 
Indeed, nigral delivery of our CDNF-t2a-MANF lentiviral vector resulted in a 
significant increase in the number of TH cell bodies in the SN as well as a strong 
preservation of the striatal TH-terminals.  Interestingly, the preservation of TH-
terminals with CDNF-t2a-MANF was higher than with CDNF alone and this was 
accompanied by a higher reduction in the number of amphetamine-induced rotations, 
suggesting a synergistic effect of the two proteins. It should be noted that CDNF 
overexpressed from the CDNF-t2a-MANF gene is not identical to the native CDNF 
12and contains 19 additional amino acids. It is conceivable these additional residues 
could affect the properties of the mature CDNF, perhaps increasing its stability, 
diffusion or receptor binding thus accounting in part for the enhanced neuroprotection 
observed with CDNF-t2a-MANF. Nonetheless, the synergistic effects of CDNF and 
MANF on neurochemical and functional recovery of the lesioned nigro-striatal 
system suggests that although CDNF and MANF belong to the same NTF family, 
they may have functional differences and mediate protective effects through different 
mechanisms 31. In this respect, lentiviral vectors have an advantage over AAV vectors 
in terms of a larger cloning capacity to accommodate multiple NTFs to be delivered 
by a single vector. 
Very few publications have tested the efficacy of the CDNF/MANF family of 
neurotrophic factors in PD models; these publications have followed the GDNF 
paradigm in which targeting the striatal afferents seems to afford optimal 
neuroprotection. To our knowledge, ours is the first study to compare alternative 
delivery sites.  Remarkably, we have shown that, unlike GDNF, intranigral CDNF 
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and MANF delivery appears to be far more efficacious than striatal delivery. This 
suggests that GDNF and the CDNF/MANF families have different modes of action 
depending on where they are delivered and may have implications for future 
therapeutic interventions. This is also the first study to demonstrate that combined 
delivery of CDNF and MANF can have synergistic effects that result in enhanced 
neuroprotection. Multiple/combined NTF delivery may therefore be more efficacious 
for the treatment of PD than the single NTF approaches attempted so far and testing 
these strategies in other models of PD or neurodegeneration - such as the -synuclein 
model of PD 11 -  is a pressing need. Additionally, it has recently been shown that 
integration-deficient lentiviral vectors, which become episomal molecules and hence 
have a much-reduced risk of causing insertional mutagenesis (Yáñez-Muñoz et al, 
2006; Wanisch and Yáñez-Muñoz, 2009), can efficiently deliver hGDNF to the 
striatum and have a neuroprotective effect in the 6-OHDA model of PD (Lu-Nguyen 
et al., 2014). Therefore, it may be possible to achieve multiple/combined NTF 
delivery in a variety of experimental paradigms using safer therapeutic vectors. 
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Figure Legends. 
Figure 1. Lentiviral vector design. All vectors contain GFP as reporter gene under the 
Spleen Focus Forming Virus (sffv) promoter, the gene of interest under the cmv 
promoter. ΔLTR: truncated Long Terminal Repeats. PBS: Primer Binding Site; RRE: 
Rev Response Element; cPPT: Poly-Purine Tract; WPRE: Woodchuck hepatitis virus 
Posttranscriptional Regulatory Element; ψ: packaging signal.  
Figure 2. Lentiviral vector validation in vitro. a) Transduction with Lenti.CDNF-GFP 
induces CDNF overexpression in HEK293T cells; b) Transduction with Lenti.MANF-
GFP induces MANF overexpression. Scale bars=100m. Immunoblotting showing; c) 
increased CDNF expression in culture supernatants and cell pellets with higher 
Lenti.CDNF-GFP MOI; d) increased MANF expression in cell pellets with 
Lenti.MANF-GFP (MOI 5); e) increased GDNF expression with higher Lenti.GDNF-
GFP MOI. -tubulin was used as an endogenous loading control; f) 
Immunocytochemistry on transduced E18 rat cortical neurons (MOI 5), left: control 
virus Lenti.GFP, Middle: transduction with Lenti.CDNF-GFP virus stained for CDNF 
(red), GFP (green) and DNA (blue). Right: transduction with Lenti.MANF-GFP virus 
stained for MANF (red), GFP (green) and DNA (blue). Scale bars = 50m. 
Figure 3. Striatal delivery of lentiviral vectors; rotational behaviour. a) Apomorphine 
induced rotations at 2, 4, 6 and 8 weeks post lesion; b) Amphetamine induced 
rotations at 8 weeks post lesion. Newman-Keuls post-hoc test, *p < 0.05, n≥6 per 
group. 
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Figure 4. a) Striatal TH-fibre density at 8 weeks post viral transduction; a) TH 
immunohistochemistry on coronal sections of the corpus striatum (Bregma +0.6), 
representative sections of Lenti.GFP, Lenti.CDNF-GFP, Lenti.MANF-GFP and 
Lenti.GDNF-GFP delivered into the striatum; b) Quantification of TH-fibre density 
by optical densitometry; c) Immunohistochemistry of TH on coronal sections of the 
substantia nigra; d) Intrastriatal delivery of CDNF or MANF fails to protect nigral 
dopamine neurons against 6-OHDA toxicity but GDNF is protective compared to 
GFP-control animals. Newman-Keuls post-hoc test, ** p < 0.01; ***p < 0.001, n≥6 
per group. 
Figure 5. Nigral delivery of lentiviral vectors; rotational behaviour. a) Apomorphine 
induced rotations at 2, 4, 6 and 8 weeks post lesion; b) Amphetamine induced 
rotations at 8 weeks post lesion. Newman-Keuls post-hoc test, * p < 0.05; **p < 0.01, 
n≥6 per group 
Figure 6. Striatal TH-fibre density at 8 weeks post viral transduction; a) TH 
immunohistochemistry on coronal sections of the corpus striatum (Bregma +0.6), 
representative sections of Lenti.GFP, Lenti.CDNF-GFP, Lenti.MANF-GFP and 
Lenti.GDNF-GFP delivered into the nigra; b) Quantification of TH-fibre density by 
optical densitometry; c) Immunohistochemistry of TH on coronal sections of the 
substantia nigra; d) Intranigral delivery of CDNF fails to protect nigral dopamine 
neurons against 6-OHDA toxicity but both MANF and GDNF are protective 
compared to GFP-control animals. Newman-Keuls post-hoc test * p < 0.05; **p < 
0.01; ***p < 0.001, n≥6 per group. 
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Figure 7. Processing of CDNF-t2a-MANF. a) translation of the CDNF-t2a-MANF 
gene as one single polypeptide; b) removal of signal peptides (SP) and t2a-induced 
self-cleaving yields four peptidic fragments, including CDNF+19 aas and native 
MANF; c) Increased intracellular CDNF and MANF as well as secreted CDNF with 
higher Lenti.CDNF-t2a-MANF-GFP MOI (+ = positive control). 
Figure 8. Nigral delivery of Lenti.CDNF-t2a-MANF-GFP (Lenti.CtM) vector.  
Intranigral Lenti.CtM-GFP reduces the number of ipsilateral rotations, increases the 
TH-striatal innervation and increases the number of surviving neurons at weeks post 
lesion. a) Apomorphine induced rotations at 2, 4, 6 and 8 weeks post lesion; b) 
Amphetamine induced rotations at 8 weeks post lesion; c) Striatal TH-fibre density at 
8 weeks post viral transduction; TH immunohistochemistry on coronal sections of the 
corpus striatum (Bregma +0.6), representative sections of Lenti.GFP and Lenti.CtM-
GFP delivered into the nigra; d) Quantification of TH-fibre density by optical 
densitometry;  e) Immunohistochemistry of TH on coronal sections of the substantia 
nigra; f) Intranigral delivery of CtM protects nigral dopamine neurons against 6-
OHDA toxicity compared to GFP-control animals.  T-test; *p < 0.05; p < 0.01**; 
***p < 0.001, n≥6 per group. 
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Supplementary figure legends 
Supplementary Figure 1 - Primer sequences. Forward primers contain 17-22bp 
complementary to the beginning of the target gene and the consensus kozak sequence 
with a XhoI restriction site immediately upstream of the starting codon (green). 
Reverse primers contain 17-22bp complementary to the end of the target gene and a 
SpeI restriction site immediately after the stop codon (red). For illustrative purposes, 
the sequence of reverse primers in the table is the reverse-complement of the actual 
PCR primers. The CDNF-t2a-MANF insert was generated by overlap-extension PCR 
involving three steps. PCR-I: (primers I & II) a XhoI restriction site and the sequence 
of the t2a self-cleaving peptide are introduced by PCR flanking the hsCDNF gene. 
PCR-II: (primers III & IV) a SpeI restriction site and the sequence of the t2a self-
cleaving peptide are introduced by PCR flanking the hsMANF gene. Extension PCR: 
(primers I & IV) XhoI-hsCDNF-t2a and t2a-hsMANF-SpeI are used as a template for 
a final PCR yielding the full-length DNA construct. PCR settings are detailed on 
Table S2 
Suppl Figure 2 - Insert sequences. Annotated sequences of the inserts cloned into 
the pRRL-sffv-eGFP-cmv backbone. 
Suppl Figure 3 - Experimental design. Nigro-striatal lesions were performed by 
unilateral injection of 10g 6-OHDA in two sites of the cortex striatum. On the same 
day, neurotrophic factors (NTF) were delivered into the Cortex striatum or the 
Substantia nigra. All stereotactic coordinates are given relative to Bregma and Dura 
(AP: antero-posterior, ML: medio-lateral, DV: dorso-ventral) The integrity of the 
nigro-striatal dopaminergic system was assessed using amphetamine and 
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apomorphine induced rotations. Animals were euthanized 8 weeks after the surgical 
procedure. 
Suppl Figure 4 - Schematic of drug-induced rotations in the hemilesioned rat. 
Left: Amphetamine induces dopamine release from surviving dopaminergic neurons. 
DA release is higher in the intact hemisphere and this imbalance results in ipsilateral 
rotations. Right: lesioned hemisphere is hyper-responsive to dopamine. Apomorphine, 
a dopamine receptor agonist causes over-activation in the lesioned hemisphere and 
leads to contralateral rotations. Right hemisphere: lesion side 
Suppl Figure 5- Lentiviral vector transduction spread. Immuno-fluorescence on 
40m coronal sections at 8 weeks following unilateral preterminal lesion with 6-
OHDA.  Lentiviral transduction in the cortex striatum following striatal delivery of  a) 
Lenti.CDNF-GFP or b) Lenti.MANF-GFP. Lentiviral transduction in the substantia 
nigra following intranigral delivery of c) Lenti.CDNF-GFP or b) Lenti.MANF-GFP.  
Sections were stained for CDNF or MANF (Red), GFP (Green) and DNA (Blue). 
Scale bars=100m 
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Cloning primers I
hsGDNF forward GA CTCGAG GCCACC ATGAAGTTATGGGATGTC
XhoI kozak
hsGDNF reverse GCTAAAAGGTGTGGATGTATCTGA ACTAGT GC
SpeI
hsMANF reverse GTGCACGGACCGATTTGTAG ACTAGT GCGCCGCG
SpeI
hsMANF forward GAATT CTCGAG GCCACC ATGTGGGCCACGCAGGGGC
XhoI kozak
hsCDNF forward GA CTCGAG GCCACC ATGTGGTGCGCGAGCCCA
XhoI kozak
hsCDNF reverse CCCCAAAACAGAGCTCTGA ACTAGT GCC
SpeI
(5’  3’)
Cloning primers II
Primer I - XhoI-hsCDNF
(5’  3’)
Primer II - hsCDNF-(Gly)-t2a
4
Primer IV - hsMANF-SpeI
Primer III - t2a-(Gly)-hsMANF
4
GCCTGCTGACCTGCGGCGACGTGGAGGAGAACCCCGGCCCC GGAGGAGGAGGA ATGTGGGCCACGCAGGGGCTGGCGGTG
Glynkt2a self-cleaving peptide
GCAGCGACACACCCCAAAACAGAGCTC GGAGGAGGAGGA GAGGGCCGCGGCAGCCTGCTGACCTGCGGCGACGTGGAGG
Glynk t2a self-cleaving peptide
TGA
GA CTCGAG GCCACC ATGTGGTGCGCGAGCCCA
XhoI kozak
GTGCACGGACCGATTTGTAG ACTAGT GCGCCGCG
SpeI
S1-Primer sequences
CTCGAG GCCACC ATGTGGTGCGCGAGCCCAGTTGCTGTGGTGGCCTTTTGCGCCGGGCTTTTGGTCTCTCACCCGG
TGCTGACGCAGGGCCAGGAGGCCGGGGGGCGGCCAGGGGCCGACTGTGAAGTATGTAAAGAATTCTTGAACCGAT
TCTACAAGTCACTGATAGACAGAGGAGTTAACTTTTCGCTGGACACTATAGAGAAAGAATTGATCAGTTTTTGCTTGG
ACACCAAAGGAAAAGAAAACCGCCTGTGCTATTATCTAGGAGCCACAAAAGACGCAGCCACAAAGATCCTAAGTGA
AGTCACTCGCCCAATGAGTGTGCATATGCCTGCAATGAAGATTTGTGAGAAGCTGAAGAAGTTGGATAGCCAGATCTG
TGAGCTGAAATATGAAAAAACACTGGACTTGGCATCAGTTGACCTGCGGAAGATGAGAGTGGCAGAGCTGAAGCAG
ATCCTGCATAGCTGGGGGGAGGAGTGCAGGGCCTGTGCAGAAAAAACTGACTATGTGAATCTCATTCAAGAGCTGG
CCCCCAAGTATGCAGCGACACACCCCAAAACAGAGCTCTGA ACTAGT
XhoI Kozak Start
Stop SpeI
XhoI-hsCDNF-SpeI
S2-Insert sequences
CTCGAG GCCACC ATGAAGTTATGGGATGTCGTGGCTGTCTGCCTGGTGCTGCTCCACACCGCGTCCGCCTTCCCGCT
GCCCGCCGGTAAGAGGCCTCCCGAGGCGCCCGCCGAAGACCGCTCCCTCGGCCGCCGCCGCGCGCCCTTCGCGCTG
AGCAGTGACTCAAATATGCCAGAGGATTATCCTGATCAGTTCGATGATGTCATGGATTTTATTCAAGCCACCATTAAAA
GACTGAAAAGGTCACCAGATAAACAAATGGCAGTGCTTCCTAGAAGAGAGCGGAATCGGCAGGCTGCAGCTGCCA
ACCCAGAGAATTCCAGAGGAAAAGGTCGGAGAGGCCAGAGGGGCAAAAACCGGGGTTGTGTCTTAACTGCAATAC
ATTTAAATGTCACTGACTTGGGTCTGGGCTATGAAACCAAGGAGGAACTGATTTTTAGGTACTGCAGCGGCTCTTGC
GATGCAGCTGAGACAACGTACGACAAAATATTGAAAAACTTATCCAGAAATAGAAGGCTGGTGAGTGACAAAGTAG
GGCAGGCATGTTGCAGACCCATCGCCTTTGATGATGACCTGTCGTTTTTAGATGATAACCTGGTTTACCATATTCTAAG
AAAGCATTCCGCTAAAAGGTGTGGATGTATCTGA ACTAGT
XhoI-hsGDNF-SpeI
XhoI Kozak Start
Stop SpeI
CTCGAG GCCACC ATGTGGGCCACGCAGGGGCTGGCGGTGGCGCTGGCTCTGAGCGTGCTGCCGGGCAGCCGGGC
GCTGCGGCCGGGCGACTGCGAAGTTTGTATTTCTTATCTGGGAAGATTTTACCAGGACCTCAAAGACAGAGATGTCA
CATTCTCACCAGCCACTATTGAAAACGAACTTATAAAGTTCTGCCGGGAAGCAAGAGGCAAAGAGAATCGGTTGTGC
TACTATATCGGGGCCACAGATGATGCAGCCACCAAAATCATCAATGAGGTATCAAAGCCTCTGGCCCACCACATCCCT
GTGGAGAAGATCTGTGAGAAGCTTAAGAAGAAGGACAGCCAGATATGTGAGCTTAAGTATGACAAGCAGATCGACC
TGAGCACAGTGGACCTGAAGAAGCTCCGAGTTAAAGAGCTGAAGAAGATTCTGGATGACTGGGGGGAGACATGCA
AAGGCTGTGCAGAAAAGTCTGACTACATCCGGAAGATAAATGAACTGATGCCTAAATATGCCCCCAAGGCAGCCAGT
GCACGGACCGATTTGTAG ACTAGT
XhoI-hsMANF-SpeI
Stop SpeI
XhoI Kozak Start
CTCGAG GCCACC ATGTGGTGCGCGAGCCCAGTTGCTGTGGTGGCCTTTTGCGCCGGGCTTTTGGTCTCTCACCCGG
TGCTGACGCAGGGCCAGGAGGCCGGGGGGCGGCCAGGGGCCGACTGTGAAGTATGTAAAGAATTCTTGAACCGAT
TCTACAAGTCACTGATAGACAGAGGAGTTAACTTTTCGCTGGACACTATAGAGAAAGAATTGATCAGTTTTTGCTTGG
ACACCAAAGGAAAAGAAAACCGCCTGTGCTATTATCTAGGAGCCACAAAAGACGCAGCCACAAAGATCCTAAGTGA
AGTCACTCGCCCAATGAGTGTGCATATGCCTGCAATGAAGATTTGTGAGAAGCTGAAGAAGTTGGATAGCCAGATCT
GTGAGCTGAAATATGAAAAAACACTGGACTTGGCATCAGTTGACCTGCGGAAGATGAGAGTGGCAGAGCTGAAGCA
GATCCTGCATAGCTGGGGGGAGGAGTGCAGGGCCTGTGCAGAAAAAACTGACTATGTGAATCTCATTCAAGAGCTG
GCCCCCAAGTATGCAGCGACACACCCCAAAACAGAGCTC GGAGGAGGAGGAGAGGGCCGCGGCAGCCTGCTGACC
TGCGGCGACGTGGAGGAGAACCCCGGCCCC GGAGGAGGAGGA ATGTGGGCCACGCAGGGGCTGGCGGTGGCGCT
GGCTCTGAGCGTGCTGCCGGGCAGCCGGGCGCTGCGGCCGGGCGACTGCGAAGTTTGTATTTCTTATCTGGGAAGA
TTTTACCAGGACCTCAAAGACAGAGATGTCACATTCTCACCAGCCACTATTGAAAACGAACTTATAAAGTTCTGCCGG
GAAGCAAGAGGCAAAGAGAATCGGTTGTGCTACTATATCGGGGCCACAGATGATGCAGCCACCAAAATCATCAATGA
GGTATCAAAGCCTCTGGCCCACCACATCCCTGTGGAGAAGATCTGTGAGAAGCTTAAGAAGAAGGACAGCCAGATAT
GTGAGCTTAAGTATGACAAGCAGATCGACCTGAGCACAGTGGACCTGAAGAAGCTCCGAGTTAAAGAGCTGAAGAA
GATTCTGGATGACTGGGGGGAGACATGCAAAGGCTGTGCAGAAAAGTCTGACTACATCCGGAAGATAAATGAACTG
ATGCCTAAATATGCCCCCAAGGCAGCCAGTGCACGGACCGATTTGTAG ACTAGT
XhoI-hsCDNF-Glynk-T2A-Glynk-hsMANF-SpeI
XhoI Kozak Start
Stop SpeI
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Experimental design
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AAV-α-Synuclein  Nigral Delivery -5.3 -2.2 -7.2
Stereotactic coordinates (mm) AP ML DV
Intra-Nigral Delivery Group
Intra-Striatal Delivery Group
S5 Viral Spread in lesioned hemisphere
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